查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1403426

遲發性治療藥物到2030年的全球市場預測：依產品類型、疾病類型、給藥途徑、配銷通路和地區進行分析

Tardive Dyskinesia Therapeutics Market Forecasts to 2030 - Global Analysis By Product Type, Disease Type, Route Of Administration, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球遲發性藥物市場規模將達到 25 億美元，預計 2030 年將達到 54 億美元，預測期內複合年成長率為 11.1%。

藥物引起的運動疾病稱為遲發性(TD)，會導致舌頭、臉部、軀幹和四肢不受控制地運動。遲發性是長期使用某些精神藥物（如抗精神病藥物）的副作用。儘管有時也會影響其他患者，但這種疾病最常見於長期服用抗精神病藥物的精神分裂症、分裂情感性疾患和躁鬱症患者。

根據 John Wiley &Sons, Inc. 於 2022 年 8 月發表的一篇論文，在歐洲接受抗精神病藥物治療的精神病患者中，遲發性的盛行率為 23.3%。

遲發性盛行率上升

提高認知可能有助於早期發現和治療，減輕症狀的嚴重。研究的進步將導致更專業的藥物和治療方法的開發，為受影響的人提供更個性化的護理。此外，提高意識將鼓勵為進一步研究提供資金籌措，激發創造力，發現治療和預防遲發性的新方法，並最終減少受這種疾病影響的人數，提高人們的生活品質。

複雜的管理

遲發性的治療通常涉及多種策略的組合，包括改變目前的治療方案或添加新的治療方案。這種複雜性可能會使治療變得困難，尤其是在兼顧控制原始藥物所治療的潛在疾病的需要時。用於控制它的治療方法可能會產生輕微到嚴重的副作用，可能需要密切監測和管理。

改善識別和診斷

早期發現可以及時治療，減緩病程並改善患者的治療效果。更多知識使醫療保健專業人員能夠積極監測患者，從而更容易快速改變處方時間表或使用其他治療方法來控制症狀。此外，增加知識有助於患者教育和支持、減少恥辱並促進富有同情心的醫療保健方法。這樣的綜合策略最終將改善人們的生活品質並促進市場擴張。

製藥公司研發投入限制

治療罕見疾病藥物研發的主要挑戰之一是能夠參與臨床試驗的患者數量較少。只有幾百、幾千名罕見疾病患者有資格參加臨床試驗。罕見疾病患者數量非常少。此外，研究費用昂貴且投資回報不明，這可能導致製藥公司不願為其提供資金。

新冠肺炎 (COVID-19) 影響：

這場大流行擾亂了全球醫療保健服務，影響了常規檢查、專家諮詢以及面對面治療的可用性。結果，許多遲發性患者的治療被推遲或中斷。 COVID-19 影響了正在進行的與遲發性相關的臨床試驗和研究的進展。由於探視限制或入組挑戰，一些臨床試驗可能會被推遲或修改。

預計在預測期內，丁苯那嗪部分將是最大的

預計Deutetrabenazine細分市場在預測期內將是最大的細分市場。氘替代延長了半衰期，提高了療效和安全性，減少了與給藥相關的副作用，並提高了患者的醫囑遵從性。這種化合物有望抑制與遲發性相關的不自主運動，從而提供更一致且更易於管理的治療方法。

遲發性肌張力不全症地區預計在預測期內複合年成長率最高

遲發性肌張力不全症領域預計在預測期內複合年成長率最高。遲發性肌張力不全症是遲發性的一種亞型，具體涉及持續的肌肉收縮，導致重複的扭轉運動和異常姿勢。調整或停用引發遲發性肌張力不全症的藥物可能會改善或消除症狀。然而，這種情況必須由醫療專業人員仔細處理，平衡藥物的益處與精神狀態惡化的風險。

比最大的地區

預計北美在預測期內將佔據最大的市場佔有率。多家製藥公司正在投資開發專門用於症狀管理的藥物。這些治療旨在透過減輕與疾病相關的不自主運動來改善受影響個體的生活品質。隨著治療方法選擇的進步以及醫療保健提供者對這些治療方法的接受程度不斷提高，市場正在呈現成長。

複合年成長率最高的地區：

由於醫療保健意識的提高、診斷技術的改進和高齡化，預計亞太地區在預測期內將保持最高的複合年成長率。製藥公司正在努力開發針對症狀的新治療方法和藥物，以解決該領域未滿足的醫療需求。國內和全球製藥公司之間的合作以及診斷和治療技術的進步也有助於該地區的市場擴張。

免費客製化服務

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球遲發性治療市場：依產品類型

  • 纈苯那嗪
  • Tetrabenazine
  • 氯硝西泮
  • 維生素E
  • 苯二氮平類
  • Ondansetron
  • Tetrabenazine
  • 賴血平
  • 普萘洛爾
  • 多巴胺消耗劑

第6章全球遲發性治療市場：依疾病類型

  • 遲發性不能
  • 遲發性口腔臉部運動障礙
  • 遲發性肌張力不全症
  • 遲發性眼瞼痙攣
  • 遲發性抽動

第7章全球遲發性治療市場：依給藥途徑

  • 口服
  • 注射

第8章全球遲發性治療藥物市場：按配銷通路

  • 醫院藥房
  • 藥局和零售藥局
  • 線上藥房
  • 其他配銷通路

第9章全球遲發性治療市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第10章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司簡介

  • Mitsubishi Tanabe Pharma Corporation
  • Luye Pharma Group
  • Teva Pharmaceutical Industries Ltd.
  • Neurocrine Biosciences, Inc.
  • SOM BIOTECH
  • Sun Pharmaceutical Industries Ltd
  • AbbVie Inc
  • Sanis
  • SteriMax Inc.
  • Adamas Pharmaceuticals, Inc
  • Reddys Laboratories Ltd
  • Mylan NV
  • Bausch Health
  • Johnson & Johnson Services
  • Lupin Pharmaceuticals Inc
  • Novartis AG
  • Baxter
  • Amgen Inc
  • Pfizer Inc
  • Medicure Inc
Product Code: SMRC24651

According to Stratistics MRC, the Global Tardive Dyskinesia Therapeutics Market is accounted for $2.5 billion in 2023 and is expected to reach $5.4 billion by 2030 growing at a CAGR of 11.1% during the forecast period. A drug-induced movement condition called tardive dyskinesia (TD) results in uncontrollably moving the tongue, face, torso, and limbs. It is a side effect brought on by extended use of specific psychiatric drug classes, such antipsychotics. Although they sometimes afflict other patients as well, the illness is most frequent among those who have been taken long-term antipsychotic drugs for schizophrenia, schizoaffective disorder, or bipolar disorder.

According to an article published by John Wiley & Sons, Inc., in August 2022, the prevalence of tardive dyskinesia in Europe is 23.3% amongst psychiatric patients receiving treatment with antipsychotics.

Market Dynamics:

Driver:

Rising prevalence of tardive dyskinesia

Increased consciousness encourages early identification and action, which may lessen the severity of symptoms. Research progresses lead to the creation of more specialized drugs and therapies, providing impacted people with more individualized care. Furthermore, greater awareness encourages financing for additional research, which spurs creativity and reveals fresh approaches to tardive dyskinesia therapy and prevention, eventually enhancing the quality of life for individuals affected by the disorder.

Restraint:

Complexity in management

The management of tardive dyskinesia frequently entails a mix of strategies, such as changing current prescriptions or adding new ones. This intricacy can make treatment difficult, particularly when juggling the requirement to manage the underlying condition for which the original medication was prescribed. Therapeutic options for management have a range of side effects, from mild to severe, which may require close monitoring and management.

Opportunity:

Increased awareness and diagnosis

Early detection enables timely management, which may slow its course and enhance patient outcomes. Increased knowledge encourages healthcare professionals to monitor patients proactively, which makes it easier to control symptoms by promptly changing prescription schedules or using other therapies. Moreover, better knowledge promotes patient education and support, lessens stigma, and encourages a more compassionate approach to healthcare. This all-encompassing strategy eventually improves people's quality of life, which fuels market expansion.

Threat:

Limited R&D investment by pharmaceutical companies

One of the major challenges of rare disease drugs in terms of research and development is the small patient population available for clinical trials. Only a few hundred or few thousand patients with rare diseases are accessible for clinical trials. Rare diseases afflict a tiny population. Furthermore, because research may be expensive and have hazy returns on investment, pharmaceutical corporations could be reluctant to fund it.

COVID-19 Impact:

The pandemic caused disruptions in healthcare services globally, affecting regular check-ups, access to specialists, and availability of in-person treatments. This led to delays or interruptions in treatment for many individuals with tardive dyskinesia. COVID-19 impacted the progress of ongoing clinical trials and research studies related to tardive dyskinesia. Some trials might have been delayed or modified due to restrictions on in-person visits and enrollment challenges.

The deutetrabenazine segment is expected to be the largest during the forecast period

The deutetrabenazine segment is expected to be the largest during the forecast period. Its deuterium substitution enhances its efficacy and safety profile by prolonging its half-life, leading to fewer dose-related side effects and improved patient adherence. This compound demonstrates potential in reducing involuntary movements associated with Tardive Dyskinesia while offering a more consistent and manageable treatment approach.

The tardive dystonia segment is expected to have the highest CAGR during the forecast period

The tardive dystonia segment is expected to have the highest CAGR during the forecast period. Tardive dystonia, a subtype of tardive dyskinesia, specifically involves sustained muscle contractions causing repetitive, twisting movements or abnormal postures. Sometimes, adjusting or discontinuing the medications that trigger tardive dystonia can lead to improvement or resolution of symptoms. However, this must be carefully managed by a healthcare professional to balance the benefits of the medication with the risk of worsening psychiatric conditions.

Region with largest share:

North America is projected to hold the largest market share during the forecast period. Several pharmaceutical companies have been investing in developing medications specifically targeted to manage symptoms. These treatments aim to alleviate the involuntary movements associated with the condition, thereby improving the quality of life for affected individuals. The market has shown growth in terms of advancements in therapeutic options and the growing acceptance of these treatments among healthcare providers.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period due to rising healthcare awareness, improving diagnostic techniques, and an aging population. Pharmaceutical companies were working on developing new treatments and medications targeting symptoms, aiming to address the unmet medical needs in this area. Collaborations between local and global pharmaceutical companies, as well as advancements in technology for diagnosis and treatment, were also contributing to the expansion of the market in the region.

Key players in the market:

Some of the key players in Tardive Dyskinesia Therapeutics market include Mitsubishi Tanabe Pharma Corporation, Luye Pharma Group, Teva Pharmaceutical Industries Ltd., Neurocrine Biosciences, Inc., SOM BIOTECH, Sun Pharmaceutical Industries Ltd, AbbVie Inc , Sanis, SteriMax Inc., Adamas Pharmaceuticals, Inc , Reddys Laboratories Ltd, Mylan N.V., Bausch Health, Johnson & Johnson Services, Lupin Pharmaceuticals Inc, Novartis AG, Baxter, Amgen Inc, Pfizer Inc and Medicure Inc.

Key Developments:

In February 2023, Teva Pharmaceuticals announced the print publication of the IMPACT-TD Scale, an easy-to-use, standardized and clinician-rated assessment. The scale, developed by a consensus panel, will assist healthcare providers in determining the impact of tardive dyskinesia (TD) on different aspects of a patient's daily functioning.

In December 2021, Mitsubishi Tanabe Pharma Corporation and Janssen Pharmaceutical K.K. have entered into a co-promotion agreement for MT-5199, a vesicular monoamine transporter type 2 (VMAT2) inhibitor, which is intended for use as tardive dyskinesia therapeutics in Japan.

Product Types Covered:

  • Valbenazine
  • Deutetrabenazine
  • Clonazepam
  • Vitamin E
  • Benzodiazepines
  • Ondansetron
  • Tetrabenazine
  • Reserpine
  • Propranolol
  • Dopamine-Depleting Agents

Disease Types Covered:

  • Tardive akathisia
  • Tardive Orofacial Dyskinesia
  • Tardive Dystonia
  • Tardive Blepharospasm
  • Tardive Tics

Route Of Administration Covered:

  • Oral
  • Injectable

Distribution Channels Covered:

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies
  • Other Distribution Channels

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Tardive Dyskinesia Therapeutics Market, By Product Type

  • 5.1 Introduction
  • 5.2 Valbenazine
  • 5.3 Deutetrabenazine
  • 5.4 Clonazepam
  • 5.5 Vitamin E
  • 5.6 Benzodiazepines
  • 5.7 Ondansetron
  • 5.8 Tetrabenazine
  • 5.9 Reserpine
  • 5.10 Propranolol
  • 5.11 Dopamine-Depleting Agents

6 Global Tardive Dyskinesia Therapeutics Market, By Disease Type

  • 6.1 Introduction
  • 6.2 Tardive akathisia
  • 6.3 Tardive Orofacial Dyskinesia
  • 6.4 Tardive Dystonia
  • 6.5 Tardive Blepharospasm
  • 6.6 Tardive Tics

7 Global Tardive Dyskinesia Therapeutics Market, By Route Of Administration

  • 7.1 Introduction
  • 7.2 Oral
  • 7.3 Injectable

8 Global Tardive Dyskinesia Therapeutics Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Hospital Pharmacies
  • 8.3 Drug Stores & Retail Pharmacies
  • 8.4 Online Pharmacies
  • 8.5 Other Distribution Channels

9 Global Tardive Dyskinesia Therapeutics Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Mitsubishi Tanabe Pharma Corporation
  • 11.2 Luye Pharma Group
  • 11.3 Teva Pharmaceutical Industries Ltd.
  • 11.4 Neurocrine Biosciences, Inc.
  • 11.5 SOM BIOTECH
  • 11.6 Sun Pharmaceutical Industries Ltd
  • 11.7 AbbVie Inc
  • 11.8 Sanis
  • 11.9 SteriMax Inc.
  • 11.10 Adamas Pharmaceuticals, Inc
  • 11.11 Reddys Laboratories Ltd
  • 11.12 Mylan N.V.
  • 11.13 Bausch Health
  • 11.14 Johnson & Johnson Services
  • 11.15 Lupin Pharmaceuticals Inc
  • 11.16 Novartis AG
  • 11.17 Baxter
  • 11.18 Amgen Inc
  • 11.19 Pfizer Inc
  • 11.20 Medicure Inc

List of Tables

  • Table 1 Global Tardive Dyskinesia Therapeutics Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Tardive Dyskinesia Therapeutics Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 3 Global Tardive Dyskinesia Therapeutics Market Outlook, By Valbenazine (2021-2030) ($MN)
  • Table 4 Global Tardive Dyskinesia Therapeutics Market Outlook, By Deutetrabenazine (2021-2030) ($MN)
  • Table 5 Global Tardive Dyskinesia Therapeutics Market Outlook, By Clonazepam (2021-2030) ($MN)
  • Table 6 Global Tardive Dyskinesia Therapeutics Market Outlook, By Vitamin E (2021-2030) ($MN)
  • Table 7 Global Tardive Dyskinesia Therapeutics Market Outlook, By Benzodiazepines (2021-2030) ($MN)
  • Table 8 Global Tardive Dyskinesia Therapeutics Market Outlook, By Ondansetron (2021-2030) ($MN)
  • Table 9 Global Tardive Dyskinesia Therapeutics Market Outlook, By Tetrabenazine (2021-2030) ($MN)
  • Table 10 Global Tardive Dyskinesia Therapeutics Market Outlook, By Reserpine (2021-2030) ($MN)
  • Table 11 Global Tardive Dyskinesia Therapeutics Market Outlook, By Propranolol (2021-2030) ($MN)
  • Table 12 Global Tardive Dyskinesia Therapeutics Market Outlook, By Dopamine-Depleting Agents (2021-2030) ($MN)
  • Table 13 Global Tardive Dyskinesia Therapeutics Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 14 Global Tardive Dyskinesia Therapeutics Market Outlook, By Tardive akathisia (2021-2030) ($MN)
  • Table 15 Global Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Orofacial Dyskinesia (2021-2030) ($MN)
  • Table 16 Global Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Dystonia (2021-2030) ($MN)
  • Table 17 Global Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Blepharospasm (2021-2030) ($MN)
  • Table 18 Global Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Tics (2021-2030) ($MN)
  • Table 19 Global Tardive Dyskinesia Therapeutics Market Outlook, By Route Of Administration (2021-2030) ($MN)
  • Table 20 Global Tardive Dyskinesia Therapeutics Market Outlook, By Oral (2021-2030) ($MN)
  • Table 21 Global Tardive Dyskinesia Therapeutics Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 22 Global Tardive Dyskinesia Therapeutics Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 23 Global Tardive Dyskinesia Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 24 Global Tardive Dyskinesia Therapeutics Market Outlook, By Drug Stores & Retail Pharmacies (2021-2030) ($MN)
  • Table 25 Global Tardive Dyskinesia Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 26 Global Tardive Dyskinesia Therapeutics Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 27 North America Tardive Dyskinesia Therapeutics Market Outlook, By Country (2021-2030) ($MN)
  • Table 28 North America Tardive Dyskinesia Therapeutics Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 29 North America Tardive Dyskinesia Therapeutics Market Outlook, By Valbenazine (2021-2030) ($MN)
  • Table 30 North America Tardive Dyskinesia Therapeutics Market Outlook, By Deutetrabenazine (2021-2030) ($MN)
  • Table 31 North America Tardive Dyskinesia Therapeutics Market Outlook, By Clonazepam (2021-2030) ($MN)
  • Table 32 North America Tardive Dyskinesia Therapeutics Market Outlook, By Vitamin E (2021-2030) ($MN)
  • Table 33 North America Tardive Dyskinesia Therapeutics Market Outlook, By Benzodiazepines (2021-2030) ($MN)
  • Table 34 North America Tardive Dyskinesia Therapeutics Market Outlook, By Ondansetron (2021-2030) ($MN)
  • Table 35 North America Tardive Dyskinesia Therapeutics Market Outlook, By Tetrabenazine (2021-2030) ($MN)
  • Table 36 North America Tardive Dyskinesia Therapeutics Market Outlook, By Reserpine (2021-2030) ($MN)
  • Table 37 North America Tardive Dyskinesia Therapeutics Market Outlook, By Propranolol (2021-2030) ($MN)
  • Table 38 North America Tardive Dyskinesia Therapeutics Market Outlook, By Dopamine-Depleting Agents (2021-2030) ($MN)
  • Table 39 North America Tardive Dyskinesia Therapeutics Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 40 North America Tardive Dyskinesia Therapeutics Market Outlook, By Tardive akathisia (2021-2030) ($MN)
  • Table 41 North America Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Orofacial Dyskinesia (2021-2030) ($MN)
  • Table 42 North America Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Dystonia (2021-2030) ($MN)
  • Table 43 North America Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Blepharospasm (2021-2030) ($MN)
  • Table 44 North America Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Tics (2021-2030) ($MN)
  • Table 45 North America Tardive Dyskinesia Therapeutics Market Outlook, By Route Of Administration (2021-2030) ($MN)
  • Table 46 North America Tardive Dyskinesia Therapeutics Market Outlook, By Oral (2021-2030) ($MN)
  • Table 47 North America Tardive Dyskinesia Therapeutics Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 48 North America Tardive Dyskinesia Therapeutics Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 49 North America Tardive Dyskinesia Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 50 North America Tardive Dyskinesia Therapeutics Market Outlook, By Drug Stores & Retail Pharmacies (2021-2030) ($MN)
  • Table 51 North America Tardive Dyskinesia Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 52 North America Tardive Dyskinesia Therapeutics Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 53 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Country (2021-2030) ($MN)
  • Table 54 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 55 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Valbenazine (2021-2030) ($MN)
  • Table 56 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Deutetrabenazine (2021-2030) ($MN)
  • Table 57 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Clonazepam (2021-2030) ($MN)
  • Table 58 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Vitamin E (2021-2030) ($MN)
  • Table 59 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Benzodiazepines (2021-2030) ($MN)
  • Table 60 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Ondansetron (2021-2030) ($MN)
  • Table 61 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Tetrabenazine (2021-2030) ($MN)
  • Table 62 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Reserpine (2021-2030) ($MN)
  • Table 63 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Propranolol (2021-2030) ($MN)
  • Table 64 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Dopamine-Depleting Agents (2021-2030) ($MN)
  • Table 65 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 66 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Tardive akathisia (2021-2030) ($MN)
  • Table 67 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Orofacial Dyskinesia (2021-2030) ($MN)
  • Table 68 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Dystonia (2021-2030) ($MN)
  • Table 69 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Blepharospasm (2021-2030) ($MN)
  • Table 70 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Tics (2021-2030) ($MN)
  • Table 71 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Route Of Administration (2021-2030) ($MN)
  • Table 72 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Oral (2021-2030) ($MN)
  • Table 73 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 74 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 75 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 76 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Drug Stores & Retail Pharmacies (2021-2030) ($MN)
  • Table 77 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 78 Europe Tardive Dyskinesia Therapeutics Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 79 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Country (2021-2030) ($MN)
  • Table 80 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 81 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Valbenazine (2021-2030) ($MN)
  • Table 82 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Deutetrabenazine (2021-2030) ($MN)
  • Table 83 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Clonazepam (2021-2030) ($MN)
  • Table 84 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Vitamin E (2021-2030) ($MN)
  • Table 85 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Benzodiazepines (2021-2030) ($MN)
  • Table 86 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Ondansetron (2021-2030) ($MN)
  • Table 87 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Tetrabenazine (2021-2030) ($MN)
  • Table 88 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Reserpine (2021-2030) ($MN)
  • Table 89 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Propranolol (2021-2030) ($MN)
  • Table 90 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Dopamine-Depleting Agents (2021-2030) ($MN)
  • Table 91 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 92 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Tardive akathisia (2021-2030) ($MN)
  • Table 93 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Orofacial Dyskinesia (2021-2030) ($MN)
  • Table 94 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Dystonia (2021-2030) ($MN)
  • Table 95 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Blepharospasm (2021-2030) ($MN)
  • Table 96 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Tics (2021-2030) ($MN)
  • Table 97 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Route Of Administration (2021-2030) ($MN)
  • Table 98 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Oral (2021-2030) ($MN)
  • Table 99 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 100 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 101 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 102 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Drug Stores & Retail Pharmacies (2021-2030) ($MN)
  • Table 103 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 104 Asia Pacific Tardive Dyskinesia Therapeutics Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 105 South America Tardive Dyskinesia Therapeutics Market Outlook, By Country (2021-2030) ($MN)
  • Table 106 South America Tardive Dyskinesia Therapeutics Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 107 South America Tardive Dyskinesia Therapeutics Market Outlook, By Valbenazine (2021-2030) ($MN)
  • Table 108 South America Tardive Dyskinesia Therapeutics Market Outlook, By Deutetrabenazine (2021-2030) ($MN)
  • Table 109 South America Tardive Dyskinesia Therapeutics Market Outlook, By Clonazepam (2021-2030) ($MN)
  • Table 110 South America Tardive Dyskinesia Therapeutics Market Outlook, By Vitamin E (2021-2030) ($MN)
  • Table 111 South America Tardive Dyskinesia Therapeutics Market Outlook, By Benzodiazepines (2021-2030) ($MN)
  • Table 112 South America Tardive Dyskinesia Therapeutics Market Outlook, By Ondansetron (2021-2030) ($MN)
  • Table 113 South America Tardive Dyskinesia Therapeutics Market Outlook, By Tetrabenazine (2021-2030) ($MN)
  • Table 114 South America Tardive Dyskinesia Therapeutics Market Outlook, By Reserpine (2021-2030) ($MN)
  • Table 115 South America Tardive Dyskinesia Therapeutics Market Outlook, By Propranolol (2021-2030) ($MN)
  • Table 116 South America Tardive Dyskinesia Therapeutics Market Outlook, By Dopamine-Depleting Agents (2021-2030) ($MN)
  • Table 117 South America Tardive Dyskinesia Therapeutics Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 118 South America Tardive Dyskinesia Therapeutics Market Outlook, By Tardive akathisia (2021-2030) ($MN)
  • Table 119 South America Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Orofacial Dyskinesia (2021-2030) ($MN)
  • Table 120 South America Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Dystonia (2021-2030) ($MN)
  • Table 121 South America Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Blepharospasm (2021-2030) ($MN)
  • Table 122 South America Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Tics (2021-2030) ($MN)
  • Table 123 South America Tardive Dyskinesia Therapeutics Market Outlook, By Route Of Administration (2021-2030) ($MN)
  • Table 124 South America Tardive Dyskinesia Therapeutics Market Outlook, By Oral (2021-2030) ($MN)
  • Table 125 South America Tardive Dyskinesia Therapeutics Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 126 South America Tardive Dyskinesia Therapeutics Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 127 South America Tardive Dyskinesia Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 128 South America Tardive Dyskinesia Therapeutics Market Outlook, By Drug Stores & Retail Pharmacies (2021-2030) ($MN)
  • Table 129 South America Tardive Dyskinesia Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 130 South America Tardive Dyskinesia Therapeutics Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 131 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Country (2021-2030) ($MN)
  • Table 132 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 133 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Valbenazine (2021-2030) ($MN)
  • Table 134 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Deutetrabenazine (2021-2030) ($MN)
  • Table 135 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Clonazepam (2021-2030) ($MN)
  • Table 136 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Vitamin E (2021-2030) ($MN)
  • Table 137 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Benzodiazepines (2021-2030) ($MN)
  • Table 138 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Ondansetron (2021-2030) ($MN)
  • Table 139 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Tetrabenazine (2021-2030) ($MN)
  • Table 140 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Reserpine (2021-2030) ($MN)
  • Table 141 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Propranolol (2021-2030) ($MN)
  • Table 142 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Dopamine-Depleting Agents (2021-2030) ($MN)
  • Table 143 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 144 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Tardive akathisia (2021-2030) ($MN)
  • Table 145 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Orofacial Dyskinesia (2021-2030) ($MN)
  • Table 146 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Dystonia (2021-2030) ($MN)
  • Table 147 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Blepharospasm (2021-2030) ($MN)
  • Table 148 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Tardive Tics (2021-2030) ($MN)
  • Table 149 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Route Of Administration (2021-2030) ($MN)
  • Table 150 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Oral (2021-2030) ($MN)
  • Table 151 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 152 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 153 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 154 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Drug Stores & Retail Pharmacies (2021-2030) ($MN)
  • Table 155 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 156 Middle East & Africa Tardive Dyskinesia Therapeutics Market Outlook, By Other Distribution Channels (2021-2030) ($MN)